{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:39:14Z","timestamp":1777927154035,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perit Dial Int"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Meropenem is a second-line agent for the treatment of peritoneal dialysis-associated peritonitis (PD peritonitis), while information on pharmacokinetics (PK) of intraperitoneal (i.p.) meropenem is limited in this patient group. The objective of the present evaluation was to assess a pharmacokinetic rationale for the selection of meropenem doses in automated PD (APD) patients based on population PK modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Data were available from a PK study in six patients undergoing APD who received a single 500 mg dose of meropenem intravenous or i.p. A population PK model was developed for plasma and dialysate concentrations ( n = 360) using Monolix. Monte Carlo simulations were carried out to assess the probability of achieving meropenem concentrations above minimum inhibitory concentrations (MICs) of 2 and 8 mg\/L, representing susceptible and less susceptible pathogens respectively, for at least 40% of the dosing interval ( T\n                      <jats:sub>&gt;MIC<\/jats:sub>\n                      \u2265 40%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A two-compartment model for each plasma and dialysate concentrations with one transit compartment for the transfer from plasma to dialysate fluid described the data well. An i.p. dose of 250 and 750 mg, for an MIC of 2 and 8 mg\/L respectively, was sufficient to attain the pharmacokinetic\/pharmacodynamic target ( T\n                      <jats:sub>&gt;MIC<\/jats:sub>\n                      \u2265 40%) in more than 90% patients in plasma and dialysate. Additionally, the model predicted that no relevant meropenem accumulation in plasma and\/or peritoneal fluid would occur with prolonged treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results suggest that an i.p. dose of 750 mg daily is optimal for pathogens with an MIC 2\u20138 mg\/L in APD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08968608231167237","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T01:40:09Z","timestamp":1683078009000},"page":"402-410","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis"],"prefix":"10.1177","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1891-4524","authenticated-orcid":false,"given":"Sami","family":"Ullah","sequence":"first","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Ursli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Fuhr","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wiesholzer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Kussmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Poeppl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Austria"},{"name":"Department of Dermatology and Tropical Medicine, Military Medical Cluster East, Austrian Armed Forces, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Taubert","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"bibr1-08968608231167237","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12321216"},{"key":"bibr2-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011121135"},{"key":"bibr3-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2018.10.013"},{"key":"bibr4-08968608231167237","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.14631218"},{"key":"bibr5-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1177\/08968608221080586"},{"key":"bibr6-08968608231167237","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2016.00078"},{"key":"bibr7-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1177\/0896860821990528"},{"key":"bibr8-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02664-15"},{"key":"bibr9-08968608231167237","unstructured":"Antony F. Monolix version 2021R1. Lixoft SAS, 2021. http:\/\/lixoft.com\/products\/monolix\/ (accessed 13 April 2023)."},{"key":"bibr10-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9081-1"},{"issue":"2","key":"bibr11-08968608231167237","volume":"24","author":"Craig WA.","year":"1997","journal-title":"Clin Infect Dis"},{"key":"bibr12-08968608231167237","unstructured":"EUCAST. Clinical breakpoints and dosing of antibiotics. v 12.0, 2022. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_12.0_Breakpoint_Tables.pdf (accessed 13 April 2023)."},{"key":"bibr13-08968608231167237","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00010109"},{"key":"bibr14-08968608231167237","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2016.00023"},{"key":"bibr15-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2016.01.012"},{"key":"bibr16-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.1988.tb02756.x"},{"key":"bibr17-08968608231167237","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2012.00155"},{"key":"bibr18-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139X.2002.00103.x"},{"key":"bibr19-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02390-17"},{"key":"bibr20-08968608231167237","doi-asserted-by":"publisher","DOI":"10.5414\/CP203790"},{"key":"bibr21-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02761-7"},{"key":"bibr22-08968608231167237","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00531-16"},{"key":"bibr23-08968608231167237","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9120931"}],"container-title":["Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08968608231167237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08968608231167237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08968608231167237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:36:16Z","timestamp":1777674976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08968608231167237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/08968608231167237"],"URL":"https:\/\/doi.org\/10.1177\/08968608231167237","relation":{},"ISSN":["0896-8608","1718-4304"],"issn-type":[{"value":"0896-8608","type":"print"},{"value":"1718-4304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}